Life Science Investing Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus 18 December 2025
Life Science Investing Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference 01 December 2025
Life Science Investing Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs 14 November 2025
